Form 8-K - Current report:
SEC Accession No. 0001356576-26-000025
Filing Date
2026-05-20
Accepted
2026-05-20 16:37:01
Documents
11
Period of Report
2026-05-17
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K supn-20260517.htm   iXBRL 8-K 31292
  Complete submission text file 0001356576-26-000025.txt   147391

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT supn-20260517.xsd EX-101.SCH 1798
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT supn-20260517_lab.xml EX-101.LAB 21884
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT supn-20260517_pre.xml EX-101.PRE 12522
14 EXTRACTED XBRL INSTANCE DOCUMENT supn-20260517_htm.xml XML 2727
Mailing Address 9715 KEY WEST AVENUE ROCKVILLE MD 20850
Business Address 9715 KEY WEST AVENUE ROCKVILLE MD 20850 301-838-2500
SUPERNUS PHARMACEUTICALS, INC. (Filer) CIK: 0001356576 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35518 | Film No.: 261004601
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)